Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Informations projet

IF-EBOla

N° de convention de subvention: 666102

DOI 10.3030/666102

Projet clôturé

Date de signature de la CE 3 Decembre 2014

Date de début 1 Novembre 2014

Date de fin 31 Octobre 2017

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 2 037 770,00

Contribution de l’UE € 1 992 770,00

Coordonné par

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
France

Livrables

Documents, reports (3)

Ebola virus diversity assessed by sequencing

The report will provide an overview of Ebola virus diversity as assessed by sequencing necessary to optimize the diagnostic, treatment and vaccine approaches.

Whole infectious profiles

The report will provide an overview of the diversity of infectious profiles from available samples.

Ethical regulations, security and safety set up for diagnostic and follow-up of patients of the phase 1 (without treatment)

Ethical regulations set up to work with the present project for diagnostic and treatment

Websites, patent fillings, videos etc. (1)

Creation of the specific website of the project

Creation of the specific website of the project.

Publications

Conference proceedings (11)

Metagenomic analyses and genomic fingerprint of co-infections of the EBOLA viral disease

Auteurs: W. Valdivia-, D. Sheoran, G. Dubois, S. Tigrett, F. Veas
Publié dans: 2015
Éditeur: Tofo conference on Filovirus, Ebola and Other Filoviruses

Development of a specific polyclonal immunoglobulin against Ebola

Auteurs: C. Herbreteau & IF Ebola
Publié dans: 2015
Éditeur: First World Congress on Targeting Ebola

Lessons Learned from the Development of an Ebola Immunotherapy

Auteurs: R Metrop, JF Saluzzo, F Veas, C. Herbreteau
Publié dans: 2017
Éditeur: IV International Conference on Mitigation Strategies for Emerging Infectious diseases

Specific polyclonal F(ab’)2immunoglobulin fragments; in vitro characterization and in vivo effectiveness in post-exposure treatment against Zaire Ebola virus in mice

Auteurs: M. Denizot, T. Racine, D. Pannetier, A. Pasquier, H. Raoul, JF Saluzzo, G. Kobinger, F. Veas, C. Herbreteau
Publié dans: 2017
Éditeur: The II International Conference CBRNE - Research & Innovation

Atypical immune response of EVD Long-term survivors

Auteurs: Y. Eskira A Sobarzo, F Veas L Lobel
Publié dans: 2017
Éditeur: VIII International Conference on Emerging Zoonoses and transboundary Infectious Diseases

The preparedness IF-EBOLA toolbox for rapid and efficient mitigation of upcoming outbreaks. A platform model for emerging diseases

Auteurs: F.Veas
Publié dans: 2016
Éditeur: International Conference on Mitigation Strategies for Emerging Infectious diseases

Efficiency of innovative preparedness IF-EBOLA technologies: Ultrasensitive diagnostics, horse anti-Ebola virus polyclonal Fabs & metagenomic analyses of Ebola variants and co-infections

Auteurs: F.Veas
Publié dans: 2017
Éditeur: IV International Conference on Mitigation Strategies for Emerging Infectious diseases

Ebola virus Genomic and Metagenomic signature Analyses of the 2014-15 West African Outbreak

Auteurs: W. Valdivia, D. Sheoran, & F. Veas
Publié dans: Numéro 7th Filovirus Conference, 2015
Éditeur: 7th Filovirus Conference

Multi-technological platforms to solve unmet needs for rapid and efficient management of emerging diseases

Auteurs: F.Veas
Publié dans: 2015
Éditeur: XIX International Congress for Tropical Diseases

A Universal virus capture method leading to a rapid and ultrasensitive detection of pathogens for early & late post-exposure countermeasures

Auteurs: S Tigrett, L Lobel, F Veas
Publié dans: 2017
Éditeur: VIII International Conference on Emerging Zoonoses and transboundary Infectious diseases

RIGEL as a Powerful Computational Architecture for Genomic & Metagenomic Signature Discrimination: Analysis of the 2014-15 West African EBOLA Outbreak”

Auteurs: W. Valdivia, D. Sheoran & F. Veas
Publié dans: Numéro Gordon Research Conferences, on Biodefense and Bioterrorism meeting, 2015, Page(s) March 8-13, 2015
Éditeur: Gordon Research Conference

Other (1)

Resveratrol-Linoleate protects from exacerbated endothelial permeability via a drastic inhibition of the MMP-9 activity

Auteurs: A Shamseddin, C Crauste, E Durand, P Villeneuve, G Dubois, T Pavlickova, Th Durand, J. Vercauteren, and F Veas
Publié dans: 2018
Éditeur: BioScience Reports 2018

Peer reviewed articles (1)

Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions

Auteurs: Aly Shamseddin, Céline Crauste, Erwann Durand, Pierre Villeneuve, Gregor Dubois, Thierry Durand, Joseph Vercauteren, Francisco Veas
Publié dans: European Journal of Lipid Science and Technology, Numéro 119/11, 2017, Page(s) 1700171, ISSN 1438-7697
Éditeur: Wiley - V C H Verlag GmbbH & Co.
DOI: 10.1002/ejlt.201700171